. 2018 Mar 27;8:5288. doi: 10.1038/s41598-018-23375-6

Table 1.

Main characteristics of trials considering ART-naïve adult patients.

Trial	Reference(s)	Enrollment period	Geographic area	No. of enrolled subjects (treated:control)	Patient characteristics at baseline: -Median/mean age - Cutoff for plasma viral load (copies/ml) - Cutoff for CD4 cell count	Duration of follow-up (weeks)	DRV group regimen	Control group regimen
*ART* - *naïve patients (8 studies* ; *4568 total patients enrolled)*
ACTG 5257	Lennox JL³⁷, Ofotokun I⁴³	2009–2011	US & Puerto Rico	1809 (601:605:603)	-37 y (median) - pVL > 1000 -CD4 not limited	96	DRV/r (800 mg/d)	Two groups: 1) ATV/r 2) RAL
ARTEMIS	Ortiz R⁴	2005–2008	US, UK, Thailand, Argentina, France, Australia	689 (343:346)	-36 y (mean) in DRV/r and 35 (mean) in LPV/r -pVL ≥ 5000 -CD4 not limited	48	DRV/r (800 mg/d)	LPV/r
	Mills AM⁵					96
	Lathouwers E¹²					96
	Orkin C¹⁰					192
ATADAR	Martinez E⁴⁴	2011	Spain	178 (88:90)	-35 y (mean) treat vs 37 y (mean) control - pVL ≥ 1000 -CD4 not limited	96	DRV/r (800 mg/d)	ATV/r
FLAMINGO	Clotet B²⁰	2011–2012	Europe, US and South America	484 (242:242)	-Adult -34 y (median age) - pVL > 1000 - CD4 not limited	48	DRV/r (800 mg/d)	DTG
FLAMINGO	Molina JM⁴⁵					96
IMEA 040 DATA trial	Slama L¹⁹	2011–2013	France	120 (61:59)	-Adult -43 y (median) - pVL > 1000 - CD4 < 200	48	DRV/r (800 mg/d)	ATV/r
METABOLIK	Aberg JA⁴⁶	NA	US	65 (34:31)	-36.5 y (median age) in the study group and 35.0 y in the control group -pVL > 1000 - CD4 not limited	48	DRV/r (800 mg/d)	ATV/r
NEAT001/ ANRS143	Raffi F⁴⁷	2010–2011	Europe	805 (401:404)	-37 y (median age) in the RAL group and 39 y (median) in the TDF-FTC group -pVL > 1000 - CD4 < 500	96	DRV/r (800 mg/d) + TDF/FTC	RAL + DRV/R (800 mg/d)
OPTIPRIM-ANRS 147	Chéret A⁴⁸	2010–2011	France	90 (45:45)	-35 y (median age) - pVL not limited - CD4 < 500	96	DRV/r (800 mg/d) + TDF/FTC	DRV/r (800 mg/d) + RAL/MVC + TDF/FTC